Electroacupuncture in the Treatment of Obesity

Fei Wang; Ji-Sheng Han
October 2008
Neurochemical Research;Oct2008, Vol. 33 Issue 10, p2023
Academic Journal
Abstract  Obesity is becoming one of the most common health problems in the world. Many other disorders, such as hypertension and diabetes are considered as the consequences of obesity. Since effective remedies are rare (only two drugs, Orlistat and Sibutramine, were officially approved by the US Food and Drug Administration for long-term obesity treatment so far), researchers are trying to discover new therapies for obesity, and acupuncture is among the most popular alternative approaches. To facilitate weight reduction, one can use manual acupuncture, electroacupuncture (EA) or transcutaneous electrical acupoint stimulation (TEAS). As the parameters of the EA or TEAS can be precisely characterized and the results are more or less reproducible, this review will focus on EA as a treatment modality for obesity. Results obtained in this laboratory in recent five years will be summarized in some detail.


Related Articles

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Jan1996, Vol. 79 Issue 1, p6 

    Reports that a Food and Drug Administration advisory panel has recommended dexfenfluramine for approval. Medication for weight loss.

  • New obesity drug approved, but will weight loss follow?  // Environmental Nutrition;Jun96, Vol. 19 Issue 6, p8 

    Reports that the Food and Drug Administration has approved the prescription obesity drug called dexfenfluramine. Chemical relationship with fenfluramine; Raising of the blood levels of serotonin; Side effects.

  • Erratum to: Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Lerner, Herbert; Whang, Joyce; Nipper, Rebecca // Surgical Endoscopy;Mar2013, Vol. 27 Issue 3, p708 

    A correction to the article "Benefit-risk Paradigm for Clinical Trial Design of Obesity Devices: FDA Proposal," in the January 26, 2013 issue is presented.

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Jun96, Vol. 79 Issue 6, p6 

    Reports on the Food and Drug Administration's (FDA) approval of dexfenfluramine hydrochloride as an anti-obesity drug intended to work on impulses in the brain that encourage people to eat. Sale of the drug under the trade name Redux; Similarities between Redux and Prozac drugs; FDA's call for a...

  • McClellan turns attention to the obesity 'epidemic' Dickinson, James G. // Medical Marketing & Media;Jul2003, Vol. 38 Issue 7, p22 

    Reports on the U.S. Food and Drug Administration's guidance preparations for assisting medical product sponsors in developing treatments for preventing obesity. Encouragement for medical innovation initiatives; Improvement of regulations and communication in product development; Emphasis on...

  • FDA advisory cites possible danger in off-label use of `fen-phen'. Dickinson, James G. // Medical Marketing & Media;Aug97, Vol. 32 Issue 8, p38 

    Focuses on the US Food & Drug Administration's (FDA) advisory involving reports of valvular heart disease in women treated for obesity with fenfluramine and phentermine drugs.

  • Fact!  // Joe Weider's Muscle & Fitness;Oct98, Vol. 59 Issue 10, p32 

    Reports on the move of Roche Holdings to withdraw its application for the United States Food and Drug Administration's (FDA) approval for the anti-obesity drug, orlistat. Side effects of orlistat.

  • New Labeling May Signal Trouble for Vivus' Qnexa.  // Bioworld Week;3/14/2011, Vol. 19 Issue 11, p2 

    The article focuses on how labeling of birth defects associated for taking topiramate affects the marketing approval of Qnexa, a drug used to treat obesity from Vivus Inc., to the U.S. Food and Drug Administration (FDA).

  • FDA advisory committee recommends approval of combination weight-loss drug. Smith, Steven R. // Endocrine Today;Jan2011, Vol. 9 Issue 1, p8 

    This article reports on the decision of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to recommend the approval of the novel combination of bupropion plus naltrexone for the treatment of obesity.


Read the Article


Sign out of this library

Other Topics